000060714 001__ 60714
000060714 005__ 20190709135447.0
000060714 0247_ $$2doi$$a10.3390/ijms18020416
000060714 0248_ $$2sideral$$a98172
000060714 037__ $$aART-2017-98172
000060714 041__ $$aeng
000060714 100__ $$0(orcid)0000-0001-9578-6525$$aLou-Bonafonte, J.$$uUniversidad de Zaragoza
000060714 245__ $$aThe search for dietary supplements to elevate or activate circulating paraoxonases
000060714 260__ $$c2017
000060714 5060_ $$aAccess copy available to the general public$$fUnrestricted
000060714 5203_ $$aLow levels of paraoxonase 1 (PON1) have been associated with the development of several pathological conditions, whereas high levels have been shown to be anti-atherosclerotic in mouse models. These findings suggest that PON1 could be a good surrogate biomarker. The other members of the family, namely PON2 and PON3, the role of which has been much less studied, deserve more attention. This paper provides a systematic review of current evidence concerning dietary supplements in that regard. Preliminary studies indicate that the response to dietary supplements may have a nutrigenetic aspect that will need to be considered in large population studies or in clinical trials. A wide range of plant preparations have been found to have a positive action, with pomegranate and some of its components being the best characterized and Aronia melanocarpa one of the most active. Flavonoids are found in the composition of all active extracts, with catechins and genistein being the most promising agents for increasing PON1 activity. However, some caveats regarding the dose, length of treatment, bioavailability, and stability of these compounds in formulations still need to be addressed. Once these issues have been resolved, these compounds could be included as nutraceuticals and functional foods capable of increasing PON1 activity, thereby helping with the long-term prevention of atherosclerosis and other chronic ailments.
000060714 536__ $$9info:eu-repo/grantAgreement/ES/CICYT-FEDER/2013-41651-R$$9info:eu-repo/grantAgreement/ES/CICYT-FEDER/2016-75441-R$$9info:eu-repo/grantAgreement/ES/DGA/B69
000060714 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000060714 590__ $$a3.687$$b2017
000060714 591__ $$aCHEMISTRY, MULTIDISCIPLINARY$$b52 / 171 = 0.304$$c2017$$dQ2$$eT1
000060714 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b90 / 292 = 0.308$$c2017$$dQ2$$eT1
000060714 592__ $$a1.26$$b2017
000060714 593__ $$aMedicine (miscellaneous)$$c2017$$dQ1
000060714 593__ $$aPhysical and Theoretical Chemistry$$c2017$$dQ1
000060714 593__ $$aComputer Science Applications$$c2017$$dQ1
000060714 593__ $$aInorganic Chemistry$$c2017$$dQ1
000060714 593__ $$aSpectroscopy$$c2017$$dQ1
000060714 593__ $$aOrganic Chemistry$$c2017$$dQ1
000060714 593__ $$aMolecular Biology$$c2017$$dQ2
000060714 593__ $$aCatalysis$$c2017$$dQ2
000060714 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000060714 700__ $$0(orcid)0000-0002-2348-8702$$aGabás-Rivera, C.
000060714 700__ $$aNavarro, M.A.
000060714 700__ $$0(orcid)0000-0002-8251-8457$$aOsada, J.$$uUniversidad de Zaragoza
000060714 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología
000060714 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000060714 773__ $$g18 (2017), 416 [18 pp]$$pInt. j. mol. sci.$$tInternational Journal of Molecular Sciences$$x1661-6596
000060714 8564_ $$s589445$$uhttps://zaguan.unizar.es/record/60714/files/texto_completo.pdf$$yVersión publicada
000060714 8564_ $$s100697$$uhttps://zaguan.unizar.es/record/60714/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000060714 909CO $$ooai:zaguan.unizar.es:60714$$particulos$$pdriver
000060714 951__ $$a2019-07-09-11:38:51
000060714 980__ $$aARTICLE